Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

6.225 +0.075 (+1.22%)
Streaming Delayed Price Updated: 11:56 AM EST, Jan 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Myriad Genetics (MYGN) Stock Trades Up, Here Is Why
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 3.7% in the afternoon session after the company signed an exclusive agreement with Zydus Lifesciences to commercialize a trio of... 
Via StockStory
News headline image
Why Myriad Genetics (MYGN) Stock Is Up Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 2.5% in the afternoon session after the company announced it would present new data from eight studies at the 2025 San Antonio... 
Via StockStory
Topics Artificial Intelligence
News headline image
Myriad Genetics (MYGN): Buy, Sell, or Hold Post Q3 Earnings?
Myriad Genetics’s 38.9% return over the past six months has outpaced the S&P 500 by 24.6%, and its stock price has climbed to $7.21 per share. This was partly due to its solid quarterly results, and... 
Via StockStory
Topics Stocks
News headline image
1 Healthcare Stock with Promising Prospects and 2 We Question
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have realized strong financial performance, and over the past... 
Via StockStory
Topics Economy Stocks
News headline image
Earnings Scheduled For November 3, 2025 ↗
 
Via Benzinga
News headline image
Why Myriad Genetics (MYGN) Stock Is Trading Lower Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 6% in the afternoon session after the U.S. Food and Drug Administration (FDA) approved a competing blood-based test for prostate... 
Via StockStory
Topics Government
News headline image
Myriad Genetics, Neogen, ICU Medical, HCA Healthcare, and Universal Health Services Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after reports revealed the Trump administration considered extending the Affordable Care Act (ACA) subsidies. These subsidies, which are government... 
Via StockStory
Topics Economy Government
News headline image
Insulet, Guardant Health, agilon health, Evolent Health, and Myriad Genetics Stocks Trade Up, What You Need To Know
A number of stocks jumped in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate cut. New York Federal Reserve President John Williams stated... 
Via StockStory
Topics Economy
News headline image
Why Myriad Genetics (MYGN) Stock Is Up Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 0.4% in the afternoon session after the company shared a positive outlook, projecting significant revenue from its hereditary... 
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
Q3 Earnings Roundup: Myriad Genetics (NASDAQ:MYGN) And The Rest Of The Therapeutics Segment
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Myriad Genetics (NASDAQ:MYGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
1 High-Flying Stock with Solid Fundamentals and 2 We Question
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices,... 
Via StockStory
Topics Artificial Intelligence Economy
News headline image
Merck, Elanco, Myriad Genetics, Neogen, and Cigna Shares Are Soaring, What You Need To Know
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid... 
Via StockStory
Topics Artificial Intelligence Stocks
News headline image
The Top 5 Analyst Questions From Myriad Genetics’s Q3 Earnings Call
Myriad Genetics’ third quarter saw revenue and adjusted profit in line with Wall Street expectations, but the market reacted negatively due to ongoing challenges in average revenue per test and... 
Via StockStory
Topics Earnings
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Myriad Genetics (MYGN) Stock Is Down Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 19.3% in the morning session after it reported mixed third-quarter results that were overshadowed by a weak earnings outlook. 
Via StockStory
Topics Economy Government World Trade
News headline image
MYGN Q3 Deep Dive: Oncology Growth and Product Launches Offset Market Headwinds
Genetic testing company Myriad Genetics (NASDAQ:MYGN) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 3.6% year on year to $205.7 million. The company’s outlook for the full year... 
Via StockStory
News headline image
Myriad Genetics’s (NASDAQ:MYGN) Q3 Earnings Results: Revenue In Line With Expectations But Stock Drops
Genetic testing company Myriad Genetics (NASDAQ:MYGN) met Wall Streets revenue expectations in Q3 CY2025, but sales fell by 3.6% year on year to $205.7 million. The company’s outlook for the full year... 
Via StockStory
News headline image
What To Expect From Myriad Genetics’s (MYGN) Q3 Earnings
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting results this Monday after the bell. Here’s what to expect. 
Via StockStory
News headline image
Exploring Myriad Genetics's Earnings Expectations ↗
 
Via Benzinga
News headline image
1 Stock Under $10 Worth Your Attention and 2 Facing Challenges
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be... 
Via StockStory
News headline image
2 Unpopular Stocks That Deserve a Second Chance and 1 That Underwhelm
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad things about a company because it can... 
Via StockStory
News headline image
3 Cash-Burning Stocks with Open Questions
While some companies burn cash to fuel expansion, others struggle to turn spending into sustainable growth. A high cash burn rate without a strong balance sheet can leave investors exposed to... 
Via StockStory
News headline image
Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump. 
Via StockStory
Topics Economy Government World Trade
News headline image
A Look Back at Therapeutics Stocks’ Q2 Earnings: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Pack
Looking back on therapeutics stocks’ Q2 earnings, we examine this quarter’s best and worst performers, including Myriad Genetics (NASDAQ:MYGN) and its peers. 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Unprofitable Stocks That Fall Short
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to convert spending into sustainable growth. 
Via StockStory
News headline image
3 Small-Cap Stocks That Concern Us
Many small-cap stocks have limited Wall Street coverage, giving savvy investors the chance to act before everyone else catches on. But the flip side is that these businesses have increased downside... 
Via StockStory
News headline image
Firing on All Cylinders: Biogen (NASDAQ:BIIB) Q2 Earnings Lead the Way
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how therapeutics stocks fared in Q2, starting with Biogen... 
Via StockStory
Topics Artificial Intelligence
News headline image
1 Momentum Stock for Long-Term Investors and 2 Facing Challenges
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro... 
Via StockStory
News headline image
3 Russell 2000 Stocks with Open Questions
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the... 
Via StockStory
Topics Regulatory Compliance
News headline image
3 Stocks Under $10 We Approach with Caution
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums). That doesn’t mean they’re bargains though, and we urge investors to be... 
Via StockStory
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.